The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Project Finance | Alive

Total Raised


Last Raised

$70M | 9 yrs ago

About Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

Alvine Pharmaceuticals Headquarter Location

75 Shoreway Road Suite B

San Carlos, California, 94070,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alvine Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alvine Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alvine Pharmaceuticals Patents

Alvine Pharmaceuticals has filed 12 patents.

patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Rare diseases, Food additives, Sugar substitutes, Inflammations


Application Date


Grant Date



Related Topics

Autoimmune diseases, Rare diseases, Food additives, Sugar substitutes, Inflammations



Latest Alvine Pharmaceuticals News

Alvine Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 2, 2016

Home » Topics » Biotechnology Business » Latest News » Alvine Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Alvine Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Alvine Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on Alvine Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Alvine Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Alvine Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Alvine Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

  • When was Alvine Pharmaceuticals founded?

    Alvine Pharmaceuticals was founded in 2005.

  • Where is Alvine Pharmaceuticals's headquarters?

    Alvine Pharmaceuticals's headquarters is located at 75 Shoreway Road, San Carlos.

  • What is Alvine Pharmaceuticals's latest funding round?

    Alvine Pharmaceuticals's latest funding round is Project Finance.

  • How much did Alvine Pharmaceuticals raise?

    Alvine Pharmaceuticals raised a total of $135.15M.

  • Who are the investors of Alvine Pharmaceuticals?

    Investors of Alvine Pharmaceuticals include AbbVie, InterWest Partners, Sofinnova Ventures, Prospect Venture Partners, Panorama Capital and 7 more.

  • Who are Alvine Pharmaceuticals's competitors?

    Competitors of Alvine Pharmaceuticals include Regulus Therapeutics, Aegerion Pharmaceuticals, Intercept Pharmaceuticals, Athenex, Anacor Pharmaceuticals and 12 more.

You May Also Like

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Mithridion is a biopharmaceutical company that discovers and develops drugs for neurodegenerative diseases, with a focus on Alzheimer's disease.

KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.